How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comCarbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone
Description:
RATIONALE: Imaging procedures, such as PET scan, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying carbon-11 acetate and fludeoxyglucose F 18 PET scan of the bone in patients with metastatic prostate cancer that has spread to the bone.
Sponsor:
University of Washington
Contacts:
Evan Y. Yu, MD (STUDY_CHAIR)Government Study Link:
NCT00392938 - Click here to see study onClinicalTrials.gov
acetate
Isotope(s):
CARBON-11
Radioisotope: C-11
Theranostic Role: PET Imaging, SPECT Imaging
T1/2 (Half-Life): 20.4 Min
Decay Mode: POSITRON β+ (99.8%), ELECTRON CAPTURE (0.2%), GAMMA
Energy: max 0.96 MeV, mean 386 keV, Gamma 511 keV
Range: N/A
Decay Daughters: B11 (Stable)
Status: FDA Approval: Carbon 11 Choline (2012)
Target(s):
- Lipid/fatty acid synthesis
Ligand Class: Small Molecules
FDG
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Glucose Transport
Ligand Class: Small Molecules
Share your feedback
Help us improve your experience